Datar Cancer Genetics Private Limited
Explore this company’s associated devices, FDA decisions and regulatory history.

Datar Cancer Genetics Private Limited
- Regulatory records
- 1
- Linked recall entries
- 0
- Headquarters
- Not reported
- Brand website
- Not reported
What the linked records show
MedtechLedger currently links 1 FDA record to the applicant name Datar Cancer Genetics Private Limited. The collection includes 1 510(k) clearance. These are records held by this publication, rather than a count of the company’s entire portfolio.
The dated entries run from May 12, 2026 to May 12, 2026. Individual filings may concern different products or changes to an existing application; review the identifier and decision scope on each record.
Product code PZM appears in 1 of the 1 linked filings. The collection spans 1 FDA product code. These figures describe the filings available here; they do not establish the company’s total device sales or market share.
Applicant mailing address recorded by FDA: F-8, D Rd., Ambad, Nasik, 422010, IN. Recorded on K260235, decision dated May 12, 2026.
Device categories in this collection
Next Generation Sequencing Based Tumor Profiling Test.
Subsidiaries and similarly named applicants can have separate records. The links below preserve the applicant and submission identifiers. Source records are linked on each filing.
Regulatory record history
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
CellDx-TissueK260235 | Datar Cancer Genetics Private Limited | 510(k) clearance | May 12, 2026 | FDA |
Source updated Nov 9, 2026. Retrieved Nov 21, 2026.
